Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?

• Main Authors: Irene Magnifico, Giulio Petronio Petronio, Noemi Venditti, Marco Alfio Cutuli, Laura Pietrangelo, Franca Vergalito, Katia Mangano, Davide Zella, Roberto Di Marco
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Pharmaceuticals
• Subjects: atopic dermatitis; skin barrier; cutaneous dysbiosis; <i>Staphylococcus aureus</i>; microbial therapy; drug delivery systems
• Online Access: https://www.mdpi.com/1424-8247/13/11/411

Atopic dermatitis (AD) is a pathological skin condition with complex aetiological mechanisms that are difficult to fully understand. Scientific evidence suggests that of all the causes, the impairment of the skin barrier and cutaneous dysbiosis together with immunological dysfunction can be considered as the two main factors involved in this pathological skin condition. The loss of the skin barrier function is often linked to dysbiosis and immunological dysfunction, with an imbalance in the ratio between the pathogen <i>Staphylococcus aureus</i> and/or other microorganisms residing in the skin. The bibliographic research was conducted on PubMed, using the following keywords: ‘atopic dermatitis’, ‘bacterial therapy’, ‘drug delivery system’ and ‘alternative therapy’. The main studies concerning microbial therapy, such as the use of bacteria and/or part thereof with microbiota transplantation, and drug delivery systems to recover skin barrier function have been summarized. The studies examined show great potential in the development of effective therapeutic strategies for AD and AD-like symptoms. Despite this promise, however, future investigative efforts should focus both on the replication of some of these studies on a larger scale, with clinical and demographic characteristics that reflect the general AD population, and on the process of standardisation, in order to produce reliable data.